J&J Gets Foothold in Head & Neck Cancer With Deal for Nanobiotix’s Lead Program
Johnson & Johnson is committing up to $60 million for global rights to a Nanobiotix therapy that enhances radiation treatment for head and neck cancer. A Phase 3 test of the nanoparticle-based therapy is expected to yield preliminary data in 2024.
